Early Biomarkers in Premanifest Huntington's Disease Gene Carriers: a Pilot Study

Recruiting now · Not applicable

Conditions studied: Huntington Disease

In brief

The goal of this clinical trial is to investigate if new, early biomarkers of the disease are available in presymptomatic genetic carriers of Huntington\'s diesase compared to healthy subjects. The main questions it aims to answer are: Does functional brain MRI is able to detect early biomarkers of the disease in genetic carriers? Does gait study by a virtual reality device can detect early biomarkers of the disease in genetic carriers? Researchers will compare genetic carriers and healthy subjects to see if new, early biomarkers of the disease can be detected .

Key facts

Study ID

NCT06626308

Run by

University Hospital, Grenoble

People needed

20

Starts

2025-02-20

Expected to finish

2026-12-01

Last updated by the study team

2025-01-20

Who can join

Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• 1. For PMGC: HD diagnosis confirmed by genetic testing (CAG triplets ≥36 in HTT gene); Unified Huntington Disease Rating Scale19 Total Motor Score (UHDRS-TMS) ≤ 5; age 18-70 years old. 2. For HC: normal neurological examination; age 18-70 years old.

You may not qualify if…

• Main exclusion criteria for both PMGC and HS will be: major ophthalmologic and psychiatric active diseases; cognitive impairment (Montreal Cognitive Assessment, MoCA score \< 25/30); gait issues related to non-neurological conditions; contraindications to brain MRI.

Where it is running

• Grenoble University Hospital — Grenoble, France (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.